{"id":1988,"date":"2026-01-23T22:22:40","date_gmt":"2026-01-23T21:22:40","guid":{"rendered":"https:\/\/studienportal-eierstockkrebs.de\/ago-ovar-28-engot-ov57\/"},"modified":"2026-02-13T12:22:27","modified_gmt":"2026-02-13T11:22:27","slug":"ago-ovar-28-engot-ov57","status":"publish","type":"post","link":"https:\/\/studienportal-eierstockkrebs.de\/tr\/ago-ovar-28-engot-ov57\/","title":{"rendered":"AGO-OVAR 28 \/ ENGOT-OV57"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"1988\" class=\"elementor elementor-1988 elementor-612\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-69fa2007 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"69fa2007\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-48cd7a65\" data-id=\"48cd7a65\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-54f48f09 elementor-widget elementor-widget-text-editor\" data-id=\"54f48f09\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<h1><strong>AGO-OVAR 28 \/ ENGOT-OV57<\/strong><\/h1><h2 class=\"blue\">Yeni tan\u0131 konmu\u015f ileri evre yumurtal\u0131k kanseri i\u00e7in kemoterapi alan hastalarda tek ba\u015f\u0131na niraparib ile niraparib ve bevacizumab kombinasyonunu de\u011ferlendiren randomize a\u00e7\u0131k etiketli bir faz III \u00e7al\u0131\u015fma<\/h2>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-461e57 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"461e57\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-30ab9451\" data-id=\"30ab9451\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-16bea2ac elementor-widget-divider--view-line elementor-widget elementor-widget-divider\" data-id=\"16bea2ac\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"divider.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t<div class=\"elementor-element elementor-element-784c505 e-flex e-con-boxed e-con e-parent\" data-id=\"784c505\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-3f55e9d elementor-widget elementor-widget-text-editor\" data-id=\"3f55e9d\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><strong>\u00c7al\u0131\u015fman\u0131n amac\u0131 nedir?<\/strong><\/p><p>Yeni tan\u0131 konmu\u015f ileri evre yumurtal\u0131k, fallop t\u00fcp\u00fc veya primer periton kanseri olan hastalarda yap\u0131lan iki b\u00fcy\u00fck k\u00fcresel \u00e7al\u0131\u015fma, \u00f6nceki platin i\u00e7eren kemoterapiye yan\u0131t veren hastalar\u0131n kemoterapiyi takiben bir PARP inhibit\u00f6r\u00fc ile idame tedavisi ald\u0131klar\u0131nda n\u00fckse kadar ge\u00e7en s\u00fcrenin uzad\u0131\u011f\u0131n\u0131 g\u00f6stermi\u015ftir. \u00c7al\u0131\u015fmalardan birinde niraparibin tek ba\u015f\u0131na etkisi, di\u011ferinde ise olaparibin bevasizumab ile birlikte etkisi ara\u015ft\u0131r\u0131lm\u0131\u015ft\u0131r. Bu durum, PARP inhibit\u00f6r\u00fc ile idame tedavisinin tek ba\u015f\u0131na yeterli olup olmad\u0131\u011f\u0131 veya bevasizumab ile kombinasyonun gerekli olup olmad\u0131\u011f\u0131 sorusunu g\u00fcndeme getirmektedir. Bu nedenle bu klinik \u00e7al\u0131\u015fman\u0131n amac\u0131, bevasizumab ile kombinasyon halinde kemoterapi ve ard\u0131ndan bevasizumab ve niraparib ile idame tedavisinin, kemoterapi ve ard\u0131ndan tek ba\u015f\u0131na niraparib ile idame tedavisinden daha etkili olup olmad\u0131\u011f\u0131n\u0131 bulmakt\u0131r.   <\/p><p><strong>\u00c7al\u0131\u015fma nas\u0131l organize edildi?<\/strong><\/p><p>Bu \u00e7al\u0131\u015fma d\u00fcnya \u00e7ap\u0131nda yakla\u015f\u0131k 200 deneme merkezinde y\u00fcr\u00fct\u00fclmektedir; toplamda yakla\u015f\u0131k 970 hastan\u0131n kat\u0131lmas\u0131 beklenmektedir.<\/p><p>Hasta \u00e7al\u0131\u015fmaya kat\u0131lmaya karar verirse, bir onay beyan\u0131 imzalanmal\u0131d\u0131r. Hastan\u0131n \u00e7al\u0131\u015fmaya kat\u0131lmaya uygun olup olmad\u0131\u011f\u0131n\u0131 kontrol etmek i\u00e7in \u00e7e\u015fitli dahil etme ve hari\u00e7 tutma kriterleri kullan\u0131l\u0131r. <\/p><p>Hasta deneme i\u00e7in uygun bir adaysa, denemenin bir par\u00e7as\u0131 olarak karboplatin ve paklitaksel ile ilk kemoterapi d\u00f6ng\u00fcs\u00fcne ba\u015flayacakt\u0131r. Ayn\u0131 zamanda hastan\u0131n mevcut t\u00fcm\u00f6r \u00f6rnekleri BRCA mutasyonu a\u00e7\u0131s\u0131ndan test edilecektir. <\/p><p>T\u00fcm\u00f6r numunesi de\u011ferlendirilebilirse, 2. kemoterapi k\u00fcr\u00fcnden \u00f6nce bir sonu\u00e7 elde edilebilirse ve hasta hala kat\u0131l\u0131m i\u00e7in uygunsa, hasta a\u015fa\u011f\u0131da listelenen tedavi kollar\u0131ndan birine tahsis edilecektir.<\/p><p><strong>Tedavi kolu 1:<\/strong> Hasta paklitaksel ve karboplatin ile 5 k\u00fcr daha kemoterapi ve kemoterapinin bitiminden sonra 3 y\u0131la kadar g\u00fcnl\u00fck olarak al\u0131nacak kaps\u00fcl \u015feklinde niraparib al\u0131r.<\/p><p><strong>Tedavi kolu 2<\/strong>: Hasta paklitaksel ve karboplatin ile 5 k\u00fcr daha kemoterapi ve bevasizumab al\u0131r. Kemoterapinin bitiminden sonra, 1 y\u0131la kadar her 3 haftada bir bevacizumab ve 3 y\u0131la kadar g\u00fcnde bir kez kaps\u00fcl olarak niraparib alacaks\u0131n\u0131z. <\/p><p>Kemoterapi s\u0131ras\u0131nda ve niraparib (+\/- bevacizumab) ile idame tedavisinin ilk y\u0131l\u0131nda hastalar her \u00fc\u00e7 haftada bir ara\u015ft\u0131rma merkezinde \u00e7al\u0131\u015fma ziyaretine \u00e7a\u011fr\u0131l\u0131r. Daha sonra, bu ziyaretler idame tedavisinin 2. ve 3. y\u0131llar\u0131nda her 12 haftada bir ger\u00e7ekle\u015ftirilecektir.   <\/p><p>Tedavi tamamland\u0131ktan sonra hastalar kontrol i\u00e7in ve ard\u0131ndan her 3 ayda bir takip randevular\u0131 i\u00e7in \u00e7a\u011fr\u0131l\u0131r.<\/p><p><strong>Herhangi bir risk var m\u0131?<\/strong><\/p><p>Bir bilgilendirme oturumu s\u0131ras\u0131nda kat\u0131l\u0131mla ili\u015fkili olas\u0131 riskler ve yan etkiler hakk\u0131nda bilgilendirileceksiniz.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-5082973e elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"5082973e\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-5ddb6c0b\" data-id=\"5ddb6c0b\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-60745914 elementor-widget-divider--view-line elementor-widget elementor-widget-divider\" data-id=\"60745914\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"divider.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-7c679c4 elementor-widget elementor-widget-text-editor\" data-id=\"7c679c4\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<h2 class=\"blue\"><strong>Kat\u0131l\u0131m ko\u015fullar\u0131<\/strong><\/h2><p><b>Bu \u00e7al\u0131\u015fma 18 ya\u015f ve \u00fczeri kad\u0131nlara a\u00e7\u0131kt\u0131r:<\/b><\/p><ul><li>FIGO evre III\/IV olan yeni te\u015fhis edilmi\u015f primer, ileri evre y\u00fcksek dereceli epitelyal yumurtal\u0131k, fallop t\u00fcp\u00fc veya primer periton kanserinden muzdarip olanlar<\/li><li>yak\u0131n zamanda t\u00fcm\u00f6r \u00e7\u0131karma ameliyat\u0131 ge\u00e7irmi\u015f veya tedavileri s\u0131ras\u0131nda t\u00fcm\u00f6r \u00e7\u0131karma ameliyat\u0131 planlanm\u0131\u015f olanlar<\/li><\/ul><ul><li>parafine g\u00f6m\u00fcl\u00fc t\u00fcm\u00f6r dokusu sa\u011flayabilmelidir<\/li><\/ul><ul><li>ECOG performans durumu (Do\u011fu Kooperatif Onkoloji Grubu&#8217;nun ya\u015fam kalitesi endeksi) 0-1 aras\u0131nda olan<\/li><li>yeterli organ ve kemik ili\u011fi fonksiyonu ve normal kan bas\u0131nc\u0131 ile<\/li><li>\u00e7al\u0131\u015fma ziyaretlerine kat\u0131lmaya istekli ve muktedir olmalar\u0131 ve \u00e7al\u0131\u015fmayla ilgili t\u00fcm prosed\u00fcrleri anlam\u0131\u015f olmalar\u0131<\/li><\/ul><p>Bununla birlikte, \u00e7al\u0131\u015fmaya kat\u0131lmak i\u00e7in kar\u015f\u0131lanmas\u0131 gereken ba\u015fka kriterler de vard\u0131r. \u0130lgilenen hastalar, bu \u00e7al\u0131\u015fman\u0131n kendileri i\u00e7in uygun olup olmad\u0131\u011f\u0131n\u0131 kontrol edebilecek bir \u00e7al\u0131\u015fma merkezindeki ara\u015ft\u0131rmac\u0131larla konu\u015fmal\u0131d\u0131r. <\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-1fcfde0f elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"1fcfde0f\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-446a1689\" data-id=\"446a1689\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-553f60c3 elementor-widget-divider--view-line elementor-widget elementor-widget-divider\" data-id=\"553f60c3\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"divider.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-2ee692e3 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"2ee692e3\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-68453482\" data-id=\"68453482\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-12e1fb14 elementor-widget elementor-widget-button\" data-id=\"12e1fb14\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"http:\/\/studienportal-eierstockkrebs.de\/deutschlandkarte\/\" target=\"_blank\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t<span class=\"elementor-button-icon\">\n\t\t\t\t<svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-arrow-right\" viewBox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M190.5 66.9l22.2-22.2c9.4-9.4 24.6-9.4 33.9 0L441 239c9.4 9.4 9.4 24.6 0 33.9L246.6 467.3c-9.4 9.4-24.6 9.4-33.9 0l-22.2-22.2c-9.5-9.5-9.3-25 .4-34.3L311.4 296H24c-13.3 0-24-10.7-24-24v-32c0-13.3 10.7-24 24-24h287.4L190.9 101.2c-9.8-9.3-10-24.8-.4-34.3z\"><\/path><\/svg>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Almanya haritas\u0131na<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-51b0d387 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"51b0d387\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-72782827\" data-id=\"72782827\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-09a1e62 elementor-widget elementor-widget-text-editor\" data-id=\"09a1e62\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Son g\u00fcncelleme tarihi 29.01.2025<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>AGO-OVAR 28 \/ ENGOT-OV57 Yeni tan\u0131 konmu\u015f ileri evre yumurtal\u0131k kanseri i\u00e7in kemoterapi alan hastalarda tek ba\u015f\u0131na niraparib ile niraparib ve bevacizumab kombinasyonunu de\u011ferlendiren randomize a\u00e7\u0131k etiketli bir faz III \u00e7al\u0131\u015fma \u00c7al\u0131\u015fman\u0131n amac\u0131 nedir? Yeni tan\u0131 konmu\u015f ileri evre yumurtal\u0131k, fallop t\u00fcp\u00fc veya primer periton kanseri olan hastalarda yap\u0131lan iki b\u00fcy\u00fck k\u00fcresel \u00e7al\u0131\u015fma, \u00f6nceki platin [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[45,47],"tags":[],"class_list":["post-1988","post","type-post","status-publish","format-standard","hentry","category-birincil-durum","category-calismalar"],"acf":[],"_links":{"self":[{"href":"https:\/\/studienportal-eierstockkrebs.de\/tr\/wp-json\/wp\/v2\/posts\/1988","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/studienportal-eierstockkrebs.de\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/studienportal-eierstockkrebs.de\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/studienportal-eierstockkrebs.de\/tr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/studienportal-eierstockkrebs.de\/tr\/wp-json\/wp\/v2\/comments?post=1988"}],"version-history":[{"count":3,"href":"https:\/\/studienportal-eierstockkrebs.de\/tr\/wp-json\/wp\/v2\/posts\/1988\/revisions"}],"predecessor-version":[{"id":2005,"href":"https:\/\/studienportal-eierstockkrebs.de\/tr\/wp-json\/wp\/v2\/posts\/1988\/revisions\/2005"}],"wp:attachment":[{"href":"https:\/\/studienportal-eierstockkrebs.de\/tr\/wp-json\/wp\/v2\/media?parent=1988"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/studienportal-eierstockkrebs.de\/tr\/wp-json\/wp\/v2\/categories?post=1988"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/studienportal-eierstockkrebs.de\/tr\/wp-json\/wp\/v2\/tags?post=1988"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}